Sign Up Today and Learn More About Kromatid Stock
Invest in or calculate the value of your shares in Kromatid or other pre-IPO companies through EquityZen, part of Morgan Stanley.
Kromatid Stock (KROM)
KromaTiD focuses on advancing the knowledge of genetic abnormalities and diseases by developing molecular cytogenetics assays and reagents.
About Kromatid Stock
Founded
2007
Headquarters
Fort Collins, CO, US
Industries
Natural Resources, Software, Artificial Intelligence
Kromatid Press Mentions
Stay in the know about the latest news on Kromatid
Longmont gene-analysis firm Kromatid elevates new leader
bizwest • Jun 23, 2026
KROMATID Names Matthew Hemstreet CEO as Company Advances Toward Market Leadership in Cell & Gene Therapy
biospace • Jun 19, 2026
KROMATID Names Matthew Hemstreet CEO as Company Advances Toward Market Leadership in Cell & Gene Therapy
prnewswire • Jun 18, 2026
KROMATID to Present Breakthrough Genomic Integrity Benchmarking at ASGCT 2026, Powering the World’s First Genomic Intelligence Platform
biospace • May 01, 2026
KROMATID to Present Breakthrough Genomic Integrity Benchmarking at ASGCT 2026, Powering the World's First Genomic Intelligence Platform
prnewswire • Apr 30, 2026
Kromatid Management
Leadership team at Kromatid
Director
Walter Young
Member Board Of Directors
Priya Gogoi
Join now and verify your accreditation status to gain access to:
- Kromatid Current Valuation
- Kromatid Stock Price
- Kromatid Management
- Available deals in Kromatid and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Kromatid Cap Table and Funding History by Share Class and Liquidity Preferences
- Kromatid Revenue and Financials
- Kromatid Highlights
- Kromatid Business Model
- Kromatid Risk Factors
- Kromatid Research Report from SACRA Research
Trading Kromatid Stock
How to invest in Kromatid stock?
Accredited investors can buy pre-IPO stock in companies like Kromatid through EquityZen funds. These investments are made available by existing Kromatid shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Kromatid stock?
Shareholders can sell their Kromatid stock through EquityZen's private company marketplace. EquityZen's network includes over 470K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 55K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
